S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space
(ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Nektar TherapeuticsAllakosFibroGenAlkermesUnited Therapeutics
SymbolNASDAQ:NKTRNASDAQ:ALLKNASDAQ:FGENNASDAQ:ALKSNASDAQ:UTHR
Price Information
Current Price$16.77$72.67$38.83$18.65$84.18
52 Week RangeHoldBuyBuyHoldHold
Analyst Ratings
Consensus RecommendationHoldBuyBuyHoldHold
Consensus Price Target$37.25N/A$58.40$27.60$125.30
% Upside from Price Target122.12% upsideN/A50.40% upside48.03% upside48.85% upside
Trade Information
Market Cap$3.01 billion$3.17 billion$3.41 billion$2.90 billion$3.69 billion
Beta2.65-1.291.841.810.95
Average Volume2,355,479450,249685,7611,170,341530,211
Sales & Book Value
Annual Revenue$1.19 billionN/A$212.96 million$1.09 billion$1.63 billion
Price / Sales2.46N/A15.852.682.27
Cashflow$3.79 per shareN/AN/A$0.63 per share$14.37 per share
Price / Cash4.43N/AN/A29.755.86
Book Value$9.92 per share$4.37 per share$6.22 per share$7.54 per share$63.98 per share
Price / Book1.69N/A6.242.471.32
Profitability
Net Income$681.31 million$-43,540,000.00$-86,420,000.00$-139,310,000.00$589.20 million
EPS$3.78($2.20)($1.03)($0.07)$13.39
Trailing P/E Ratio4.44N/AN/AN/A6.29
Forward P/E RatioN/AN/AN/AN/A8.99
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-354.90%N/A13.90%-17.10%-7.69%
Return on Equity (ROE)-25.25%-36.97%9.01%-4.13%-4.54%
Return on Assets (ROA)-19.52%-34.45%5.66%-2.63%-3.26%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.22%N/A0.07%0.25%0.31%
Current Ratio14.09%16.58%9.73%2.98%4.62%
Quick Ratio13.97%16.58%9.71%2.69%4.41%
Ownership Information
Institutional Ownership Percentage93.32%58.38%69.54%95.90%94.31%
Insider Ownership Percentage4.02%52.11%7.83%4.71%8.80%
Miscellaneous
Employees618624612,300860
Shares Outstanding175.27 million43.19 million86.92 million157.13 million43.85 million
Next Earnings Date11/6/2019 (Estimated)11/14/2019 (Estimated)11/14/2019 (Estimated)10/23/2019 (Confirmed)10/30/2019 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableOptionable
 Nektar TherapeuticsAllakosFibroGenAlkermesUnited Therapeutics

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel